SG11202111877TA - Method for treating cough by using diaminopyrimidine compound - Google Patents

Method for treating cough by using diaminopyrimidine compound

Info

Publication number
SG11202111877TA
SG11202111877TA SG11202111877TA SG11202111877TA SG11202111877TA SG 11202111877T A SG11202111877T A SG 11202111877TA SG 11202111877T A SG11202111877T A SG 11202111877TA SG 11202111877T A SG11202111877T A SG 11202111877TA SG 11202111877T A SG11202111877T A SG 11202111877TA
Authority
SG
Singapore
Prior art keywords
treating cough
diaminopyrimidine compound
diaminopyrimidine
compound
cough
Prior art date
Application number
SG11202111877TA
Inventor
Yanping Zhao
Hongjun Wang
Huai Huang
Yuanyuan Jiang
Huining Liang
Ran An
Zhou Lan
Jin Wang
Liying Zhou
Yanan Liu
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of SG11202111877TA publication Critical patent/SG11202111877TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202111877TA 2019-04-30 2020-04-29 Method for treating cough by using diaminopyrimidine compound SG11202111877TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019085180 2019-04-30
PCT/CN2020/087686 WO2020221274A1 (en) 2019-04-30 2020-04-29 Method for treating cough by using diaminopyrimidine compound

Publications (1)

Publication Number Publication Date
SG11202111877TA true SG11202111877TA (en) 2021-11-29

Family

ID=73029672

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111877TA SG11202111877TA (en) 2019-04-30 2020-04-29 Method for treating cough by using diaminopyrimidine compound

Country Status (12)

Country Link
US (1) US20220211703A1 (en)
EP (1) EP3960179A4 (en)
JP (1) JP2022530890A (en)
KR (1) KR20220007620A (en)
CN (1) CN114007619B (en)
AU (1) AU2020265327A1 (en)
BR (1) BR112021021600A2 (en)
CA (1) CA3138780A1 (en)
MX (1) MX2021013338A (en)
SG (1) SG11202111877TA (en)
TW (1) TWI736243B (en)
WO (1) WO2020221274A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019085916A1 (en) * 2017-11-01 2019-05-09 北京泰德制药股份有限公司 P2x3 and/or p2x2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1725540B1 (en) * 2004-03-05 2012-09-12 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
JP5128603B2 (en) 2006-10-04 2013-01-23 エフ．ホフマン−ラ ロシュ アーゲー Method for the synthesis of phenoxydiaminopyrimidine derivatives
JP6546592B2 (en) * 2013-08-23 2019-07-17 アファレント ファーマシューティカルズ インコーポレイテッド Diaminopyrimidine P2X3 and P2X2 / 3 receptor modulators for treating acute, subacute or chronic cough
ES2942711T3 (en) * 2015-09-29 2023-06-06 Afferent Pharmaceuticals Inc Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough
MA43821A (en) * 2016-03-14 2018-11-28 Afferent Pharmaceuticals Inc PYRIMIDINS AND VARIANTS THEREOF, AND THEIR USES
CA3018180C (en) * 2016-03-25 2024-02-20 Ronald Charles Hawley Pyrimidines and variants thereof, and uses therefor
WO2019085916A1 (en) * 2017-11-01 2019-05-09 北京泰德制药股份有限公司 P2x3 and/or p2x2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof

Also Published As

Publication number Publication date
JP2022530890A (en) 2022-07-04
US20220211703A1 (en) 2022-07-07
CN114007619B (en) 2024-08-06
BR112021021600A2 (en) 2022-01-04
WO2020221274A1 (en) 2020-11-05
CA3138780A1 (en) 2020-11-05
TWI736243B (en) 2021-08-11
MX2021013338A (en) 2022-01-24
AU2020265327A1 (en) 2021-12-16
EP3960179A4 (en) 2023-01-25
TW202106302A (en) 2021-02-16
CN114007619A (en) 2022-02-01
EP3960179A1 (en) 2022-03-02
KR20220007620A (en) 2022-01-18

Similar Documents

Publication Publication Date Title
ZA201906302B (en) Method for improving tobacco-planting soil by using biochar
GB201907244D0 (en) Method
EP3991184C0 (en) Method for producing 225actinium from 226radium
GB201909562D0 (en) Method
GB201911286D0 (en) Method
GB201907782D0 (en) Method
GB201917742D0 (en) Method
SG11202111877TA (en) Method for treating cough by using diaminopyrimidine compound
GB201912863D0 (en) Novel method
GB201910759D0 (en) Method
GB201900940D0 (en) Method
SG11202111960PA (en) Method for treating endometriosis-associated pain by using diaminopyrimidine compound
SG11202111060VA (en) Method for producing perfluoroalkyne compound
SG11202103673UA (en) Method for producing perfluorocycloalkene compound
GB201917060D0 (en) Method
GB201910404D0 (en) Method
GB201901532D0 (en) Method
GB201918364D0 (en) Novel method
GB201914513D0 (en) Novel Method
EP4038198C0 (en) Method
GB201917806D0 (en) Method
GB201917638D0 (en) Method
GB201917599D0 (en) Method
GB201916388D0 (en) Method
GB201916390D0 (en) Method